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Background: Chronic obstructive pulmonary disease (COPD) is a clinical syndrome encompassing a group of
chronic, progressive, and debilitating respiratory conditions, that are characterized by incompletely reversible airflow
limitation. Within the Asia-Pacific region, prevalence estimates have been derived using various protocols and study
methods, and there is little data on the impact of COPD exacerbations. This study aimed to provide a comprehensive
picture of the current prevalence and burden of COPD in this region.
Methods: A population-based survey was conducted in nine Asia-Pacific territories between 01 February 2012 and 16
May 2012. Overall, 112,330 households were screened to identify eligible subjects (aged ≥40 years, with a physician
diagnosis of COPD, chronic bronchitis or emphysema, or with identifiable symptoms of chronic bronchitis). Out of a
sample of 69,279 individuals aged ≥40 years, 4,289 subjects with COPD were identified. Data were collected via face-to-
face interviews or by fixed-line telephone, using a structured questionnaire. A total of 1,841 completed questionnaires
were analyzed.
Results: The overall estimated COPD prevalence was 6.2%, with 19.1% of subjects having severe COPD. In the
12 months prior to the survey, nearly half of all subjects (46%) had experienced exacerbations, and 19% had been
hospitalized as a result of their condition. When subjects were asked about the impact of their condition on
employment, 23% said their condition kept them from working, and 42% felt that their condition limited their ability to
work or their activities. Of those who reported taking prescription drugs, 20% did not know the name of the drugs
they were taking. Prescription of oral corticosteroids was common, with 44% of subjects having used these during the
previous year to manage their respiratory symptoms; in contrast, inhaler use was low (25%). Only 37% of subjects had
taken a lung function test, and the majority (89%) of those tested did not know their test results.
Conclusions: Across the Asia-Pacific territories surveyed, the prevalence of COPD is high, indicating a substantial
socioeconomic burden. Our findings suggest that there is considerable room for improvement in the management of
COPD, and highlight a need to enhance patient and physician education in the region.
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Chronic obstructive pulmonary disease (COPD) is a clin-
ical syndrome that encompasses a group of chronic,
progressive, and debilitating respiratory conditions, in-
cluding emphysema and chronic bronchitis. COPD is
the fourth leading cause of global mortality [1], and its
prevalence is predicted to rise [2,3]. Despite the wealth
of information regarding its causes, pathophysiology,
and treatment options, the disease has historically been
under-diagnosed and under-reported, especially within
the Asia-Pacific region [1,4].
COPD is characterized by persistent, progressive air-
flow limitation, and is often accompanied by cough and
increased sputum production [4]. Airflow limitation is
associated with chronic inflammation in the lungs and is
principally caused by long-term exposure to airborne ir-
ritants such as cigarette smoke. In the Asia-Pacific re-
gion, smoke from biomass fuels and industrial toxins are
also known to be problematic risk factors [5-7]. The
symptoms of COPD cause significant impairment of
quality of life (QoL), including breathlessness, anxiety,
and physical limitations, resulting in days of missed
work [8].
COPD exacerbations, consisting of an acute worsening
of the usual symptoms beyond normal day-to-day vari-
ation, can be particularly debilitating [4]. While some ex-
acerbations may be relatively mild and go unreported
[9], in severe cases they can be particularly debilitating,
requiring weeks for full recovery [10]. Recent studies
have indicated that there may be exacerbation-specific
phenotypes [11,12], and that cough and sputum (chronic
bronchitis) are associated with a greater exacerbation
frequency [13,14].
Previous studies of the prevalence of COPD and its ex-
acerbations in the Asia-Pacific have focused on individ-
ual countries or cities [15-19], or relied on mathematical
modeling [20]. The Epidemiology and Impact of COPD
(EPIC) Asia survey is the first population-based COPD
survey to cover nine Asia-Pacific regions using the same
study design and questionnaire. We collected data on
COPD exacerbation and its indicators, such as cough
and sputum, as these aspects of the disease have not
been well documented in this region. We also consid-
ered measures of disease reporting, disease severity, and
socioeconomic factors, along with treatment and man-
agement practices. The aim was to gain further insight
regarding the current prevalence and burden of COPD
in the Asia-Pacific region.
Methods
The EPIC survey was conducted between 01 February
2012 and 16 May 2012 in nine Asia-Pacific territories:
China, Hong Kong, and Taiwan (North Asia), and
Indonesia, Malaysia, the Philippines, Singapore, Thailand,and Vietnam (Southeast Asia). Household screening and
subject selection were carried out by telephone or face-to-
face interviews (Figure 1; Additional file 1: Table S1). A
structured questionnaire was then administered to eligible
subjects.
Households were screened by random sampling to re-
duce selection bias. Fixed-line random digit dialing
(RDD) sampling was conducted in regions with a high
coverage of fixed telephone lines. Numbers were chosen
based on randomly selected blocks of numbers. In the
remaining regions, area probability (cluster) sampling was
conducted face-to-face (FF) in subjects’ homes. Areas
were divided into primary sampling units, which were
then randomly selected, and a block or building was
chosen as a starting point.
Individuals who met the following criteria were eligible
for inclusion in the survey: individuals aged ≥40 years,
who reported either a physician diagnosis of the follow-
ing: emphysema, chronic bronchitis, COPD, chronic ob-
structive airways disease, or chronic obstructive lung
disease; or who met the following symptomatic defin-
ition of chronic bronchitis: production of phlegm or
mucus from the lungs on all or most days for three con-
secutive months. As this was a community survey which
did not include any research intervention, no ethical ap-
proval was required. Verbal consent was obtained from all
subjects prior to participation in the survey. Participation
was voluntary. Subjects were informed that their results
may be published in scientific articles and their responses
would be kept both anonymous and confidential.
The structured questionnaire used for data collection
was based on those used in previous studies [21,22], with
additional questions to capture information on exacerba-
tions. This questionnaire was developed and implemented
by Abt SRBI, Inc., on behalf of Takeda Pharmaceuticals.
The same questionnaire and study design were utilized
across all territories. Where necessary, the English lan-
guage questionnaire was translated by a local translator to
the local language and then reviewed by an independent
translator with health research experience, as well as by
local medical experts. During data collection, potential
bias was mitigated by random sampling within households
containing more than one eligible individual, multiple
contact attempts to reduce contact failure, and quality
control during interviews. The fieldwork teams received
extensive training in all aspects of administering the ques-
tionnaire. Mock and pre-test interviews were used to con-
firm training standards and identify areas for modification.
Only eligible subjects who completed the study ques-
tionnaire were included in the analyses, which involved
standard descriptive statistics. Disease prevalence was
calculated as (100 × number of eligible subjects ÷ num-
ber of individuals aged ≥40 years), and expressed as a
percentage. Severe COPD was defined based on subjects’
Figure 1 Sampling strategy and response rate for the EPIC Asia survey. ‘Study subjects’ refers to the subset of individuals aged ≥40 years who
were identified as having COPD, based on the definitions used in this study (see Methods), and who completed the questionnaire.
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ing to the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) criteria (GOLD grade III or IV), or
using the following symptomatic definition: presence of
the symptoms of chronic bronchitis, together with two
or more exacerbations in the previous 12 months.
Results
Subject demographics
In the nine territories surveyed, a total of 112,330 house-
holds were screened, identifying 69,279 households with
one or more individuals aged ≥40 years. Of the 69,279
individuals aged ≥40 years, 4,289 either had a physician’s
diagnosis of COPD or met the symptomatic definition
used in this survey. Of these 4,289 subjects with identified
COPD, a total of 1,841 subjects completed the question-
naire (Figure 1). Almost half of the study population (44%)
was between 45 and 60 years of age, and 56% were female.For country-specific figures, please refer to Additional file 1:
Table S1. The mean interview duration was 41 minutes.
Estimated prevalence of COPD and related conditions
Based on the above criteria, the overall estimated preva-
lence of COPD was 6.2%, ranging from 4.5% in Indonesia
to 9.5% in Taiwan (Table 1). The proportion of subjects
with a physician diagnosis of COPD was 59%, with the re-
mainder having the symptomatic definition. Physician
diagnosis was higher in North Asia (72–93%) than in
Southeast Asia (19–60%), with the exception of Vietnam
(92%). Overall, 19.1% of the subjects met the definition of
the severe phenotype used in this study, ranging from
12.5% in Malaysia to 37.5% in Vietnam (Table 1). The ma-
jority of subjects reported their COPD classification as
GOLD stage I or II (34.1% and 37.9%, respectively), with
only a minority reporting it as stage III (9.3%) or IV (2.1%)
(Table 1). However, Southeast Asian countries had higher
Table 1 Subject demographics
Overall North Asia Southeast Asia
Self-reported
characteristic
EPIC Asia
n = 1,841
China
n = 215
Hong Kong
n = 205
Taiwan
n = 207
Indonesia
n = 200
Malaysia
n = 200
Philippines
n = 200
Singapore
n = 200
Thailand
n = 214
Vietnam
n = 200
Age (years), %
40–44 26 45 50 46 18 12 16 18 18 10
45–49 19 28 28 30 14 14 15 10 14 18
50–54 14 9 10 8 18 19 13 9 15 22
55–59 11 4 4 3 13 16 14 13 15 15
60–64 11 6 2 4 16 15 19 18 11 12
65+ 20 7 5 9 22 26 23 34 28 25
Gender, %
Female 56 40 47 60 49 67 63 59 64 60
Work status, %
Employed 47 66 75 68 36 31 37 30 40 40
Smoking, %
Never smoked on a
regular basis
58 45 53 60 53 69 56 68 55 64
COPD prevalence, %
EPIC Asia 6.2 8.1 7.7 9.5 4.5 5.1 4.2 5.9 5.3 9.4
Prevalence estimation
models [20]
6.3 6.5 3.5 5.4 5.6 4.7 3.5 6.3 5.0 6.7
Severe symptomatic
phenotype
19.1 13.0 16.1 24.2 20.5 12.5 13.0 20.0 15.9 37.5
Diagnosed vs symptomatic
(Mean age of diagnosis/yrs)
59 vs 41
(44 vs 40)
72 vs 28
(43 vs 41)
90 vs 10
(42 vs 42)
93 vs 7
(43 vs 46)
60 vs 40
(42 vs 35)
33 vs 67
(44 vs 40)
40 vs 60
(46 vs 38)
19 vs 81
(46 vs 38)
33 vs 67
(45 vs 41)
92 vs 8
(50 vs 50)
MRC dyspnea score
(mean) [23]
2.3 1.8 2.2 2.2 2.6 2.4 2.6 2.4 2.1 2.5
GOLD stage of severity
[4], %
Stage I – Mild 34.1 44.7 52.2 44.0 28.0 26.5 30.5 27.0 20.6 32.5
Stage II – Moderate 37.9 32.1 32.2 34.8 44.0 34.0 35.5 48.5 36.0 44.5
Stage III – Severe 9.3 5.6 2.9 4.8 16.5 9.5 5.0 13.5 9.3 17.5
Stage IV – Very severe 2.1 0.9 1.0 0.5 <0.5 2.5 4.0 4.0 4.2 2.0
Not diagnosed/not told 11.2 14.4 10.2 13.5 6.5 14.5 6.5 4.5 28.0 1.5
Don’t know 5.3 2.3 1.0 2.4 5.0 13.0 18.5 2.5 1.9 2.0
Other frequent health
conditions, %
None 45 61 61 63 47 47 29 39 18 40
Nasal allergies 13 18 20 15 2 3 11 2 32 14
Arthritis 11 7 11 6 5 6 19 4 13 24
Asthma 19 1 5 2 17 21 40 33 48 7
Diabetes 10 5 4 4 8 18 10 24 17 4
Hypertension 21 9 8 5 13 23 23 36 42 28
Heart disease 5 <1 2 1 7 11 6 5 8 5
General health status, %
Excellent 2 2 <1 1 9 <1 <1 <1 <1 <1
Very good 3 9 2 5 2 6 3 2 <1 <1
Good 17 17 14 12 13 25 20 19 26 6
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Table 1 Subject demographics (Continued)
Fair 48 61 70 69 33 22 58 33 53 37
Poor 23 9 13 10 35 40 19 15 19 54
Very poor 6 2 1 4 8 7 <1 32 2 5
Subjects from each of the nine territories were sampled either by telephone, using random digit dialing (RDD), or face-to-face (FF) interviews in their local language, to
identify individuals who had either received a physician diagnosis of COPD or met the symptomatic criteria used (see Methods).
A total of 1,841 subjects completed the study questionnaire for the EPIC Asia survey. All figures are percentages of subjects from the respective territory, with the
exception of mean age of COPD diagnosis and mean MRC dyspnea score.
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The mean MRC dyspnea score [23] was 2.3.
Health status and disease symptoms
There was a clear North/Southeast division in reported
health status (Table 1). The proportion of subjects who re-
port that their health was ‘poor’ or worse ranged from 11–
14% in North Asia to 19–59% in Southeast Asia. Similarly,
the proportion who considered their general health to be
‘fair’ varied from 22% in Malaysia to 70% in Hong Kong.
Overall, a substantial proportion of subjects (33–53%)
reported symptoms typical of COPD at least twice a week
during their worst month in the previous 12 months
(Additional file 2: Figure S1). Overall, 34% of the subjects
reported that physical exertion instigated their COPD
symptoms (Additional file 2: Figure S1D).
Exacerbations and unplanned healthcare utilization
Almost half (46%) of all subjects reported experiencing
exacerbations in the 12 months prior to the survey
(Figure 2A). The frequency and seasonal variation of re-
ported exacerbations is shown in Figure 2B and C. The
median number of exacerbations reported was 3, with
all territories falling within the range of 2–4 (Figure 2B).
Exacerbations occurred more frequently between October
and January (Figure 2C). For the North Asian territories
and the Philippines, an increase in exacerbations was also
seen in the months from February to April. Subjects
reported worsening of their disease symptoms during ex-
acerbations, with over half of the subjects reporting
coughing up phlegm or sputum, or coughing during the
day (Additional file 2: Figure S2).
Overall, a sizable proportion of study subjects reported
visiting a hospital emergency room (26%), or making
other unscheduled visits to a doctor or clinic (32%) in
the previous 12 months, as a result of their condition
(Figure 3A). China (46%), Hong Kong (59%), and Taiwan
(59%) recorded the highest percentages of unscheduled
doctor or clinic visits (Figure 3A). Overall, 19% of study
subjects reported being hospitalized in the previous
12 months as a result of their condition (Figure 3B).
Impact of disease on employment and daily activities
Less than half (47%) of all subjects were employed (either
full- or part-time), with the employment rate in NorthAsia being higher (66–75%) than in Southeast Asia (30–
40%) (Figure 4A). A substantial proportion of subjects
(23%) reported that their condition kept them from work-
ing (Figure 4B), particularly in Indonesia (44%) and in the
Philippines (51%). In addition, 42% felt that their condi-
tion limited the kind or amount of work they could do, or
limited their activities (Figure 4B). Subjects were also
asked to estimate their levels of productivity on a typical
day, and on a day when symptoms were at their worst.
Overall, average estimated productivity was 72% on a typ-
ical day, falling to 45% when the condition was at its worst
(Figure 4C).
The impact of disease symptoms on daily activities
was also explored (Additional file 2: Figure S3). Notably,
39% reported that their condition limited normal phys-
ical activities, such as walking. A substantial proportion
of subjects (27–49%) said that their respiratory symp-
toms placed restrictions on a range of daily activities, in-
cluding sleep, household chores, social or recreational
activities, or affected their sex life (Additional file 2:
Figure S3, A–C).
Disease management
Most subjects reported seeing either a specialist (44%)
or general practitioner (34%) for their condition. How-
ever, only 37% of study subjects reported that they had
been given a lung function test. Of those tested, 89% did
not know their test results (either forced expiratory vol-
ume in the first second [FEV1] value, or percent pre-
dicted FEV1). Of those who reported taking prescription
drugs, 20% did not know the name of the drugs they
were taking. When subjects were asked to describe the
delivery format of their medication, 57% stated pill/cap-
sule, 13% stated inhaler with spacer, and 12% stated in-
haler without spacer (Figure 5). In addition, 44% of the
subjects reported the use of oral corticosteroids to man-
age their symptoms during the previous 12 months
(Figure 6). Overall, 35% of the subjects had taken anti-
biotics for respiratory infections during the previous
12 months, and 13% had received an influenza vaccination.
Perceptions of disease and attitudes toward physician
advice
Subjects were asked questions related to their perception
of their condition. More than one-third (35%) felt that
Figure 2 Prevalence, frequency, and seasonal variation of exacerbations. (A) Proportion of study subjects who reported experiencing one or
more exacerbations within the 12 months prior to the survey. (B) Median number of exacerbations reported by subjects over this period.
(C) Proportion of subjects who reported exacerbations within each month over this period.
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(Additional file 2: Figure S4A). The majority of subjects
(76%) believed that smoking was the cause of their con-
dition, and 70% felt that their condition worsened with
increasing age, regardless of treatment (Additional file 2:
Figure S4B). However, most subjects felt that with ap-
propriate treatments, progressive increase in breathless-
ness could be slowed (86%) or they could lead a full and
active life (84%) (Additional file 2: Figure S4C).
When asked about the extent to which their doctor’s
advice regarding treatment and management helped im-
prove their condition, 43% said ‘a lot’ (Additional file 2:
Figure S5A). When subjects were asked about the extent
to which their doctor’s advice regarding lifestyle andhabits helped, a similar percentage of subjects (39%) said
‘a lot’ (Additional file 2: Figure S5B).
Discussion
The EPIC Asia survey was a multi-country, cross-sectional,
population-based study that examined the prevalence and
burden of COPD in the participating Asian territories,
from the perspective of individuals who were diagnosed
with the disease or who reported symptoms of the disease.
This approach contrasts with previous studies in Asia,
which have tended to focus on individual countries or
areas within countries [15-19].
Using data obtained from the nine Asian territories in
this population-based survey, the average prevalence of
Figure 3 Unplanned healthcare utilization. (A) Proportion of subjects who either visited a hospital emergency room or made unscheduled visit(s)
to a doctor or clinic as a result of their condition, in the 12 months prior to the survey. (B) Subjects who had ever been hospitalized because of
their condition (n; %) were asked how many times they had been hospitalized in the previous 12 months. The proportions of subjects who had
been hospitalized 0, 1, 2, or 3 or more times are indicated by the shading within each bar. Results are shown only for subjects who were able to
report the number of times they had been hospitalized.
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identified subjects were categorized as having severe or
very severe COPD, based on recalled disease classification
by a physician, or on their reported symptoms of chronic
bronchitis and frequent exacerbations. The prevalence of
COPD estimated in this study is similar to that reported
by Tan et al. who used a mathematical model to estimate
the prevalence of COPD in this region (6.3%) [20]. Simi-
larly, it is consistent with the pooled global prevalence
(7.6%) obtained from a meta-analysis of 37 population-
based COPD studies using different definitions of COPD
including spirometric criteria, patient-reported diagnoses,
physician diagnoses, etc. [24]. However, a population-
based study which employed spirometric measurements
to estimate the prevalence of COPD in 12 countries (the
BOLD study), revealed higher COPD estimates (world-
wide 10.1%; participating Asian countries 11.4–13.9%)
compared with our study. The BOLD study also showed
higher levels of severe COPD in the participating Asian
countries (1.7–5.0%) [25]. Given that identification of
COPD in our study was based on subject-reported phys-
ician diagnoses and subjects’ perception of their condition
and symptoms, it is likely that the actual prevalence of
COPD in the participating Asian territories is higher than
was estimated.The results of this survey may not be directly com-
parable to those of other COPD studies, due to differ-
ences in measurement methodology or study population.
Nevertheless, our findings and those of other studies in
Asia and elsewhere [15,16,22,24-26] indicate that COPD
represents a substantial socioeconomic burden in this
region and worldwide. In this study, a large proportion
of subjects reported that their condition restricted their
work or activities (42%), or kept them from working
altogether (23%). Another noteworthy finding is the high
rate of hospitalization reported; almost a fifth (19%) of
subjects said they had been hospitalized as a result of
their condition in the previous year. Unplanned health-
care utilization was also common, with a substantial
proportion of subjects visiting a hospital emergency
room (26%), or making unscheduled doctor or clinic
visits (32%) in the year prior to the survey. In the BOLD
study, patients with COPD reported poorer health status
than those without COPD; the degree of impairment
was greater with increasing COPD severity. Further-
more, patients regarded severe COPD to have a greater
negative impact on their health status than diabetes and
cardiovascular [26].
Other findings from our study suggest an urgent need
for improved clinical management in this region, as well
Figure 4 Impact of disease on employment and work productivity. (A) Employment status of study subjects. (B) Proportion of subjects who
reported that their condition kept them from working, limited the kind or amount of work they could do, or limited their activities. (C) Subjects’
estimated level of productivity on a typical day, and on a day when symptoms are at their worst. Upper row of n values: subjects who answered
the question regarding productivity on a typical day; lower row of n values: subjects who answered the question regarding their worst day.
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low proportion of subjects had undergone lung function
tests (37%), and the majority of those tested did not
know their test results (either FEV1 value or percent pre-
dicted FEV1). A fifth of those who reported taking pre-
scription drugs did not know the name of the drugs they
were taking. From the perspective of recommended clin-
ical practice, oral corticosteroids appear to be over-
prescribed, whereas the use of inhalers is low.
Most studies on COPD are conducted on a selected
population who are smokers. Although smoking history is
important for COPD diagnosis, environmental pollutants,such as industrial toxins and smoke from biomass fuels,
are also highly relevant risk factors, particularly in the
Asia-Pacific region [5-7]. Further, smoking status tends to
be under-reported [27]. Inclusion of both self-reported
smokers and non-smokers in this survey allows the capture
of important information on subjects who are smokers but
do not accurately report their smoking status, or those
whose COPD may be caused by environmental pollutants.
Our findings need to be interpreted within the limita-
tions of the study. Firstly, identification of COPD in sub-
jects was based on subject-reported physician diagnoses,
where available, or on the presence of self-reported
Figure 6 Use of oral corticosteroids. All study subjects (upper row of n values) were asked if they had been told to use oral steroids to manage
their respiratory symptoms in the past 12 months. Those who had been prescribed steroids (lower row of n values) were asked if they had been
told to take the steroids for three days or longer.
Figure 5 Delivery format of prescribed medication. Subjects who reported taking a prescription drug were asked about the delivery format of
their medication. Numbers below the bars indicate the total number of valid answers for this question, for the corresponding territory. Results are
shown only for subjects who were able to report the delivery format of their medication.
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severity was based either on subjects’ recall of GOLD
classification by a physician, where available, or on their
recall of symptomatic criteria. As this was a community
survey, subjects were screened based on their reported
information; there was no confirmation of diagnoses via
subject diaries or spirometric measurements. Conse-
quently, there is potential underdiagnosis, as well as mis-
classification of COPD and disease severity due to recall
bias and subjects’ misperception of their disease condition
or symptoms. This may lead to less reliable prevalence es-
timates. Secondly, subjects who were interviewed via the
telephone were likely to have higher social economic sta-
tus than those who had face-to-face interview. This could
result in a selection bias. Potential bias was minimized by
conducting random sampling both in regions with high
coverage of fixed telephone lines, as well as in those areas
without telephone access.
Another limitation of this study is the low response
rate which could have introduced the potential for re-
sponse bias. Subjects were unable to participate in the
survey due to various reasons which included ineligible
or refusal to participate, contact failure, and inability to
complete survey. Hence, it was not possible to collect
demographics information from the non-respondents to
assess if response bias exists. Nonetheless, steps were
taken to mitigate potential bias. Households were ran-
domly selected by RDD or area probability sampling. In
households where more than 1 subject was eligible, ran-
dom sampling was performed to select only 1 subject. In
addition, multiple contact attempts were made to reduce
contact failure. Another limitation of this study is that
the sample size of each country may not be large enough
to allow meaningful conclusions to be drawn about each
country. Nevertheless, the study enrolled a near uniform
number of subjects in each country that minimized the
likelihood that the overall prevalence would be affected
by unbalanced sample size in any country.
Conclusions
The results of the EPIC Asia population-based survey sug-
gest a high prevalence of COPD in the participating Asia-
Pacific territories, and indicate a substantial socioeconomic
burden of the disease in this region. Individuals with the
disease reported substantial limitations in their daily activ-
ities and loss in work productivity. These findings highlight
the need to enhance patient and physician education, and
improve the management of COPD in this region.
Additional files
Additional file 1: Table S1. Sampling frame for the EPIC Asia survey, by
country. Subjects from each of the nine participating territories were
sampled either by telephone, using random digit dialing (RDD), or face-to-face (FF) interviews in their local language, to identify individuals who
had either received a physician diagnosis of COPD or who met the
symptomatic criteria used (see Methods).
Additional file 2: Figure S1. Frequency of COPD symptoms
experienced over the previous 12 months. Proportion of subjects who
experienced the following COPD symptoms at least twice per week in
their worst month over this period: (A) being awakened at night either
by coughing or shortness of breath, (B) coughing or shortness of breath
during the day, (C) coughing up phlegm or wheezing, or (D) tightness of
the chest or coughing, wheezing, shortness of breath, or chest tightness
due to physical exertion. Figure S2. Exacerbation symptoms. The types
of symptoms reported to be elevated during exacerbation episodes, as
reported by subjects who experienced exacerbations in the 12 months
prior to the survey. Figure S3. Restriction of daily activities by COPD
symptoms. The proportion of subjects who reported that their symptoms
impose ‘some’ limitation or limit their activities ‘a lot’ with respect to:
(A) sports and recreation and normal activities such as walking, (B) social
activities or sleeping, and (C) housekeeping chores or their sex life.
Figure S4. Subjects’ attitudes to COPD. The proportion of subjects who
‘agreed’ or ‘agreed strongly’ that: (A) there are no truly effective
treatments for their condition; (B) smoking is the cause of their condition,
and that their condition tends to get worse as they get older; (C) with
proper treatment, a progressive increase in breathlessness can be slowed,
and that most people with the condition can live a full and active life.
Figure S5. Subjects’ attitudes to their physician’s advice. The proportion
of subjects who reported that their physician’s advice on (A) management
and treatment, or (B) modification of lifestyle and habits, improved their
ability to manage their respiratory symptoms to the following degrees: ‘Not
at all’, ‘Only a little’, ‘Some’, or ‘A lot’. Results are shown only for subjects
who provided valid answers to the questions.
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